@svkm-iop.ac.in
Assistant Professot, Department of Pharmaceutics
Shri Vile Parle Kelavani Mandal's, Institute of Pharmacy, Dhule
Dr. Kiran Patil is an accomplished researcher with over a decade of experience in pharmaceuticals and drug delivery systems. His journey began at R. C. Patel Institute of Pharmaceutical Education and Research Shirpur, culminating in a postgraduate degree in 2012. During his Ph.D., he pioneered surface-functionalized gelatin nanoparticles using a quality-by-design approach, revolutionizing drug delivery. Their focus on utilizing these nanoparticles to administer linezolid for tuberculosis treatment underwent rigorous testing, showcasing their commitment to combatting this disease. With expertise in formulating drug delivery systems and an impressive publication record of over 25 research papers in high-impact journals, he is a trailblazer in the field, contributing significantly to advancements in pharmaceutical sciences.
Ph.D. in Pharmaceutical Sciences
M. Pharmacy in Pharmaceutics
Pharmacology, Toxicology and Pharmaceutics, Pharmaceutical Science, Drug Discovery
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Shashikant B. Bagade, Kiran D. Patil, Ketan V. Hatware, Prashant L. Pingale, and Sonali V. Chaudhari Mhatre
A and V Publications
Biometric authentication is an efficient system associated with a person’s behavioural and physiological characteristics. The palm vein technology is a promising technology to recognize and identify the vein patterns of a person’s palm as a personal identification tool. The vein patterns of the palm exist beneath the skin and hence, it is very difficult to forge. Moreover, the palm vein patterns for every patient, including twins are different and unique. However, this pattern is persistent throughout the lifetime of the patient. This technology can be ideally useful for recognizing specific patients and keeping their records more accurately. The accuracy of this technology is not affected by factors like skin diseases, injuries, surface and subcutaneous nature of the palm. The technology is non-invasive and aseptic for use in public areas. This biometric authentication system will be useful for inpatients, outpatients and patients in ICU, emergency wards, even unconscious patients too. As there are lots of similarities in many patient’s names, birth dates, etc. there are many chances of errors in the authentication process. These errors lead to mismatch and interchange of the data resulting in serious issues. In order to minimize all these problems, palm vein technology will be the best tool. In this review, the authors discussed palm vein technology, its significance and the way this system is applicable in biometric authentication of patients and their safety.
Yogeeta O. Agrawal, Kiran D. Patil, Kamini R. More, Mohd Usman Mohd Siddique, Saad Alkahtani, Nada H. Aljarba, and Md Saquib Hasnain
Elsevier BV
Mrugendra Bhojraj Potdar, Neetesh Kumar Jain, Kiran Dayaram Patil, and Yogeeta Sameer Goyal
EManuscript Technologies
Yogeeta.O. Agrawal, Muzammil Husain, Kiran D. Patil, Vishal Sodgir, Tulshidas S. Patil, Vinit V. Agnihotri, Hitendra S. Mahajan, Charu Sharma, Shreesh Ojha, and Sameer N. Goyal
Elsevier BV
Shashikant B Bagade, Shivanee Vyas, Amit B. Page, and Kiran D. Patil
De Gruyter
Yogeeta Agrawal, Kiran Patil, Hitendra Mahajan, Mrugendra Potdar, Pratiksha Joshi, Kartik Nakhate, Charu Sharma, Sameer N. Goyal, and Shreesh Ojha
Informa UK Limited
Abstract Entacapone, a reversible catechol-o-methyl transferase inhibitor, is used to enhance the action of dopamine agonists by reducing their metabolism and the ‘Wearing-off’ effects associated with long-term use in the treatment of Parkinson's disease. It is used as an adjunct to levodopa/Carbidopa therapy. Due to limited dissolution and first-pass clearance, it suffers low and variable bioavailability issues. To overcome this problem, the present study aims to explore the potential of nanostructured lipid carriers (NLCs) for the delivery of Entacapone. The Quality by Design (QbD) approach was used for the systematic development of NLCs. The 23 full factorial designs were investigated using Design-Expert®11 software. The three independent variables namely content of total lipid (X1), surfactant (X2), and sonication time (X3) were optimized against two responses namely particle size and entrapment efficiency. The optimized NLCs were characterized for their size, surface morphology, entrapment efficiency, drug release, thermal and crystallographic studies. In-vivo pharmacokinetic studies in Entacapone-loaded NLCs showed an increase in t 1/2, AUC0–∞, MRT compared to free drug. The reduction in elimination (Kel) depicts the prolonged action of Entacapone by loading in NLCs. The results displayed Entacapone-loaded NLCs have promising potential for oral delivery and enhanced therapeutic effect which otherwise was a major issue.
Swapnil Patil, S G Gattani, Pradip Nirbhavane, O P Katare, and Kiran Patil
Informa UK Limited
ABSTRACT In the present research work, Rifabutin, drug used for tuberculosis infection, was encapsulated in lipidic nanoparticles with a view to develop a sustained release oral formulation. The nanocarrier loaded rifabutin, prepared by the solvent diffusion evaporation method and evaluated for its physical (nanoparticles size distribution) and chemical (drug content) stability. To optimize the identified independent variables, Box-Behnken Design (BBD) was utilized effectively. The result showed that a size of optimized formulation was found to be 315 ± 10.96 nm and PDI of 0.310 ± 0.05; the encapsulation efficiency was found to be (66.3 ± 3.85). On encapsulation, the nanocarrier showed amorphous pattern of drug studied using X-ray Diffractometric analysis. The release pattern of rifabutin loaded nanocarrier revealed that it represents the sustained release kinetics in comparison to plain drug. Thus, nanotechnology-based formulation may reduce frequency, provide medications more efficaciously, ultimately reducing patient avoidance.
K. D. Patil, S. B. Bagade, and S. C. Bonde
Informa UK Limited
ABSTRACT The present study explores the therapeutic potential of gelatin nanoparticles as a carrier for the delivery of linezolid, a repurposed drug for the treatment of Mycobactrium tuberculosis. However, it has significant issues of large dose and toxicity. To overcome this problem, linezolid loaded mannosylated gelatin nanoparticles were prepared for specific targeting to alveolar macrophages. The system was characterised for in-vitro , ex-vivo and in-vivo pharmacokinetics, biodistribution and toxicity studies to evaluate the safety and efficacy of the formulation. The method resulted in small-sized (197–298 nm) nanoparticles with a low polydispersity index (0.127–0.148) and higher drug entrapment (51–56%). The formulation was capable of sustained drug release with a significant increase in mean residence time and the half-life. The system is capable of reducing the dose, dosing frequency, and toxic adverse effects, which ultimately improves patient compliance and, therefore, a promising approach for the effective management of tuberculosis.
Sanjay Sharma, Ketan Hatware, Prashant Bhadane, and Kiran Patil
Bentham Science Publishers Ltd.
Abstract: Bilastine (BIL) is the new generation antihistamine that is used to relieve the symptoms of hayfever, chronic urticaria and other forms of allergic rhinitis. Chemically it is known 2-[4-[2-[4-[1- (2-ethoxyethyl) benzimidazole-2-yl] piperidine-1-yl] ethyl] phenyl]-2-methylpropane acid. The chemical structure of BIL having a hydrophilic carboxylic substituent. BIL has a longer duration of action due to its potent binding affinity to the H1 receptor. This review summarizes the properties, characteristics, chemistry along with analytical and bioanalytical methods used for estimation of BIL from different scientific articles. The literature has demonstrated some methods for quantification of BIL in various sample matrix and pharmaceutical products. Frequently and extensively used antihistaminics are in the clinic practice, a novel, effective, economic and safe analytical methodology is required for routine quality control analysis, bioavailability, and bioequivalence studies. Furthermore, this narrative review summarizes available data on chemistry, pharmacology and analysis of BIL in a different matrix.
Eswar Sairam Ravipati, Nikhil Nitin Mahajan, Sanjay Sharma, Ketan V. Hatware, and Kiran Patil
Informa UK Limited
Abstract In every developed and developing country, the major facing problem is heavy metals toxicity. Due to there is an increase in the heavy metals anthropogenic in day to day life by various factors, which are causing serious issues or harmful health hazardous for all types of living organisms. Moreover, they are present everywhere in the universe it causes the contamination of the food, dietary, and processed materials. Accordingly, the present review article further summarizes the studies related to the determination of lead as a toxic impurity with a total of 134 references in the period 2000 to 2018. In this write-up, emphasize the one of the highly toxic heavy metal element Lead (Pb) and it’s toxicity in the animals, humans, plants, and aquatic systems. In addition, the purpose of this article is to evaluate the effectiveness of established analytical techniques and trends in analytical methods like AAS; ICP-OES; ICP-MS; ASV; X-ray fluorescence spectrometry, these techniques significantly applicable for the quantitative analysis of Pb in various sources. The various regulatory authorities for Pb throughout the globe like IOSH, EPA, EMA, and CDCSO. This reveals the need and scope of further research in the field of heavy metal toxicity and development of new analytical techniques in meeting the needs of the life scientists. The present comprehensive review is an attempt to transform the state of knowledge into the findings that may act as a guideline for all the interested groups at different levels.
K.D. Patil, S.B. Bagade, and S.C. Bonde
Elsevier BV
Kiran Dayaram Patil, S. B. Bagade, and S. C. Bonde
Springer Science and Business Media LLC
Sanjay Sharma, Raksha Sharma, Ketan Hatware, and Kiran Patil
Bentham Science Publishers Ltd.
This article provides comprehensive and collective facts about teneligliptin. Teneligliptin is a dipeptide peptidase-4 (DPP-4) inhibitor that belongs to the third generation, used in the management of type 2 diabetes. It inhibits human DPP-4 enzyme activity. This drug falls under class 3; it interacts with S1, S2, and S2E extensive sub-sites. Teneligliptin and its metabolites are mainly determined in the human plasma matrix by hyphenated chromatographic methods. These developed methods could be foreseen for their clinical applications. Moreover, the stress degradation studies of Teneligliptin under different stress conditions provide an insight into degradation pathways and help in the elucidation of the structure of the degradation products by liquid mass spectroscopy. These methods are also used for routine quality control analysis of teneligliptin in pharmaceutical dosage forms.
Ketan Vinayakrao Hatware, Sanjay Sharma, Kiran Patil, Harpalsing Rajput, and Gaurav Gupta
Begell House
This review delineates the potential of naturally occurring substances for coronary artery disease (CAD), mainly coronary ischemia and its management, with their active constituents and probable mechanisms of action. As per the WHO, statistical incidence of CAD has increased in several countries. The number of coronary events worldwide has been increasing, and may increase even more in the near future. Meanwhile, increased sedentary behavior and poor diet will encourage the prevalence of CAD worldwide. As far as treatment is concerned, current conventional therapies have limitations due to their increased adverse events. The current approach to the management of CAD has certain lacunas that need to be overcome. Thus, new therapeutic options should be explored using traditional literature and current scientific data on natural products. The present review article deals with current knowledge associated with naturally occurring substances for the management of CAD.
Sanjay Sharma, Komal S. Aware, Ketan Hatware, and Kiran Patil
Bentham Science Publishers Ltd.
This review refers to the all-inclusive details of Lorcaserin Hydrochloride on comprehensive information about the synthesis, analytical methods, pharmacodynamics, pharmacokinetics, drug interactions and adverse effects. Lorcaserin Hydrochloride is chemically (R)-8-Chloro-1-methyl-2,3,4,5- tetrahydro-1H-3-benzazepine hydrochloride. Lorcaserin HCl is a novel, synthetic, centrally-acting selective serotonin C (5-HT2c) receptor, l agonist, which results in increased satiety and decreased food consumption in patients. Headache, dizziness and nausea are the most common side effects associated with this drug. Lorcaserin HCl has two major metabolites, one conjugated with glucuronide called N-carbamoyl glucuronide which is excreted in urine and the second Lorcaserin N-sulfamate, which is circulated in the blood. Lorcaserin HCl is synthesized using four different schemes of which a six-step method that resulted in 92.3% yield with 99.8% of purity is employed for scale-up production. It is analyzed quantitatively in the plasma and brain tissue matrix of rats by Ultra Performance Liquid chromatographic (UPLC) method using MS-MS (Mass Spectrometric) detection.
ShashikantB Bagade, KiranD Patil, SanjayR Sharma, and KetanV Hatware
Medknow
The WHO reports that billions of people and animals in tropical and subtropical regions are affected by helminthiasis as neglected tropical disease. It is predominant in underdeveloped areas; nevertheless, the increase in the number of travelers and migrants has made this infection more common. The current mass drug treatment produces severe side effects and many strains of helminths are resistant to them. None of the chemotherapeutic drugs meets the ideal requirements of anthelmintics, such as broad spectrum of activity, single dose cure, free from side effect and cost-effectiveness. Today, many researchers are screening the traditional herbal system in search of the anthelmintic herbal constituents which overcome all the problems of synthetic drugs. Several researchers proclaim anthelmintic activity of herbal medicines by using different experimental models. The present review demonstrates natural product drug discovery, outlining potential of herbal constituents from natural sources as natural leads against helminthiasis.
Rupesh Kumar Gautam, Gaurav Gupta, Sanjay Sharma, Ketan Hatware, Kiran Patil, Komal Sharma, Swapnil Goyal, Dinesh Kumar Chellappan, and Kamal Dua
Wiley
AbstractAimThe purpose of our investigation is to evaluate the anti‐arthritic potential of isolated rosmarinic acid from the rind of Punica granatum.MethodRosmarinic acid was isolated by bioactivity‐guided isolation from butanolic fraction of Punica granatum and acute toxicity of rosmarinic acid was carried out. The experiment was conducted at doses of 25 and 50 mg/kg, in Freund's complete adjuvant (FCA)‐induced arthritic rats. Various parameters, that is arthritic score, paw volume, thickness of paw, hematological, antioxidant and inflammatory parameters such as glutathione (GSH), superoxide dismutase (SOD), malonaldehyde (MDA) and tumor necrosis factor‐α (TNF‐α) were also estimated.ResultsRosmarinic acid significantly decreased the arthritic score, paw volume, joint diameter, white blood cell count and erythrocyte sedimentation rate. It also significantly increased body weight, hemoglobin and red blood cells. The significantly decreased levels of TNF‐α were observed in treated groups as compared to arthritic control rats (P < 0.001). At the same time antioxidant parameters (like GSH and SOD) were increased significantly while levels of MDA were significantly decreased (P < 0.001).ConclusionThe outcome of the present research concludes that rosmarinic acid showed significant anti‐arthritic potential in FCA‐induced arthritis in Wistar rats. This study represented the therapeutic role of rosmarinic acid from Punica granatum for the management of arthritis/rheumatoid arthritis/osteoarthritis and related inflammatory complications with negligible side effects which was still far from complete mitigation with available conventional medicines.
Sravani Karri, Sanjay Sharma, Ketan Hatware, and Kiran Patil
Elsevier BV
Ajay Patle, Ketan Vinayakrao Hatware, Kiran Patil, Sanjay Sharma, and Gaurav Gupta
Begell House
BACKGROUND
Urolithiasis is the most common renal system pathology; it affects the health of a many people. Because urolithiasis leads to severe pain, it influences the patient in many aspects. The management of urolithiasis is essential. Herein, we discuss the limitations of the management of urolithiasis with conventional drugs and the possibilities of using natural or herbal pharmacologically active agents beyond conventional drugs.
PURPOSE
The drugs presently used for the treatment of urolithiasis have many adverse side effects; therefore, alternatives are needed. Traditional literature suggests that many herbal or natural medicines can be easily made available for the management of urolithiasis and its consequences.
METHOD
The data used for this study were collected from various research /review articles, Internet sources, and text books. Literature regarding epidemiology and pharmacological studies performed by various researchers were taken into consideration in this review. The data from the last few decades, reported in different formats, were analyzed.
CONCLUSION
The present review reveals the severity of the progression of the occurrence of urolithiasis worldwide. The epidemiology gave in this review clearly indicates that stress-related factors and dietary complications, the key factors in the development of urolithiasis. are increasing. In this review, we acknowledge the limitations of conventional therapy. Many natural drug options are abundantly available throughout the world and can be useful for the management of urolithiasis. Future Perspectives: The development of a suitable formulation of bioactive components obtained from natural sources is being widely researched. However, traditional remedies that are very helpful in the management of urolithiasis and its related complications require scientific support and appropriate standardization for the assessment of their quality and dosage.
Akshay Patil, Vijay Mishra, Sourav Thakur, Bushra Riyaz, Amanjot Kaur, Rubiya Khursheed, Kiran Patil, and Bhushankumar Sathe
Bentham Science Publishers Ltd.
Background: In recent years, nanotechnology is gaining more attention of analytical and biomedical researchers. Nanotechnology derived nanotools deal with the nanoscale length size (i.e., 10-9 m). The particles having size below 100 nm displayed improved properties for attaining increased efficacy, better patient compliance, improved biodistribution and site-specific drug delivery. Method: Google, PubMed, Web of Science portals have been searched for potentially relevant literature to get latest developments and updated information related to different aspects of nanotechnology derived nanocarriers including biomedical applications. BResults: Available literature demonstrated that nanotechnology-based nanocarriers like liposomes, dendrimers, polymeric micelles, carbon dots, quantum dots, carbon nanotubes, magnetic nanoparticles, silica nanoparticles, silver nanoparticles and gold nanoparticles have enormous potential applications in the pharmaceutical field. The current review focuses on the drug delivery, bioimaging, tissue engineering and therapeutic applications of different nanotools. Besides these, scope and opportunities, as well as the global market scenario of nanotechnology derived nanotools, have also been discussed. Conclusion: The practice of nanotechnology in the arena of medicine will transform the strategies of detection and treatment of a wide range of diseases in the upcoming years.
Ketan Vinayakrao Hatware, Sanjay Sharma, Kiran Patil, Meghanath Shete, Sravani Karri, and Gaurav Gupta
Elsevier BV
Kiran Patil, Shashikant Bagade, Smita Bonde, Sanjay Sharma, and Gaurav Saraogi
Elsevier BV